oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
Company profile
Ticker
ONCSQ
Exchange
Website
CEO
Daniel O'Connor
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NetVentory Solutions, Inc.
SEC CIK
Corporate docs
IRS number
980573252
ONCSQ stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
10 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Jun 23
8-K
Bankruptcy or Receivership
14 Jun 23
8-K
Departure of Directors or Certain Officers
14 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Jun 23
D
Indefinite amount in options / securities to be acquired, 7 investors
26 May 23
8-K
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
18 May 23
424B5
Prospectus supplement for primary offering
18 May 23
8-K
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
16 May 23
8-K
Other Events
27 Apr 23
Transcripts
Latest ownership filings
SC 13G/A
SZOP MULTISTRAT LP
13 Feb 24
SC 13G
INTRACOASTAL CAPITAL, LLC
25 May 23
SC 13G
SZOP Multistrat Management LLC
19 May 23
SC 13G
Lind Global Fund II LP
17 Apr 23
SC 13G/A
Avidity Partners Management LP
14 Feb 23
4
Robert J DelAversano
9 Feb 23
4
Robert J DelAversano
4 Nov 22
4
Spahr Stephany Foster
12 Oct 22
3
Spahr Stephany Foster
12 Oct 22
4
Robert J DelAversano
5 Aug 22
Financial summary
Quarter (USD) | Jan 23 | Oct 22 | Jul 22 | Apr 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jul 22 | Jul 21 | Jul 20 | Jul 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.68 mm | 3.68 mm | 3.68 mm | 3.68 mm | 3.68 mm | 3.68 mm |
Cash burn (monthly) | 682.12 k | 1.80 mm | 2.55 mm | 2.79 mm | 2.20 mm | 2.08 mm |
Cash used (since last report) | 9.95 mm | 26.20 mm | 37.27 mm | 40.76 mm | 32.15 mm | 30.39 mm |
Cash remaining | -6.27 mm | -22.51 mm | -33.59 mm | -37.08 mm | -28.47 mm | -26.70 mm |
Runway (months of cash) | -9.2 | -12.5 | -13.1 | -13.3 | -12.9 | -12.8 |
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 2 |
Closed positions | 7 |
Increased positions | 4 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 35.20 mm |
Total shares | 16.91 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
China Grand Pharmaceutical & Healthcare | 10.00 mm | $18.60 mm |
Avidity Partners Management | 2.95 mm | $2.19 mm |
Alpha | 1.72 mm | $11.63 mm |
Vanguard | 731.52 k | $543.00 k |
BK Bank Of New York Mellon | 383.49 k | $285.00 k |
Salzhauer Michael | 296.28 k | $220.00 k |
Geode Capital Management | 272.25 k | $201.00 k |
Tocqueville Asset Management | 74.50 k | $55.00 k |
Renaissance Technologies | 72.90 k | $54.00 k |
Long Focus Capital Management | 69.23 k | $51.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Feb 23 | DelAversano Robert J | Common Stock | Sell | Dispose S | No | No | 1.37 | 40 | 54.80 | 1,008 |
4 Nov 22 | DelAversano Robert J | Common Stock | Sell | Dispose S | No | No | 0.37 | 283 | 104.71 | 22,975 |